Literature DB >> 32128622

ALK detection in lung cancer: identification of atypical and cryptic ALK rearrangements using an optimal algorithm.

Yuanyuan Liu1, Shafei Wu1, Xiaohua Shi1, Zhiyong Liang1, Xuan Zeng2.   

Abstract

PURPOSE: IHC, FISH, and NGS are common methods of ALK evaluation in NSCLC. The purpose of this study was to investigate whether ALK false positives or false negatives occurred more often in daily routines. An approach to identify ALK fusion was then proposed.
MATERIALS AND METHODS: We analyzed 1815 cases of NSCLC, including 83 (4.6%) ALK IHC positives. Total 182 samples (62 ALK+ and 120 ALK-) were examined via FISH, RT-ddPCR, NGS, RT-qPCR and RNAscope to confirm ALK status.
RESULTS: One ALK FISH false negative was found, which harbored two genomic rearrangements involved in EML4-ALK (exon 13:exon 20) fusion. One ALK IHC false negative was confirmed depending on a rare ALK FISH-positive pattern and ALK RNAscope positive but ALK fusion was not found via NGS. In addition, an atypical ALK FISH-positive pattern was observed in an IHC-positive case with chromosome 2 inversion leading to EML4-ALK (exon 6:exon 20) fusion. EML4-ALK fusion was determined in one case with an atypical FISH patterns by RT-qPCR. Rare complicated genomic rearrangements involved in a novel ALK fusion of EML4-ALK (exon 7:exon 14) were distinguished in an ALK IHC and FISH double-positive case.
CONCLUSION: False negative of ALK IHC, FISH and NGS results were found in our cohort, but none was false ALK positive. False ALK negatives should be more concerned than false positives. ALK rearrangements with cryptic ALK fusion patterns could be identified using our algorithm. Non-squamous non-small cell lung cancer was recommended for priority detection.

Entities:  

Keywords:  Anaplastic lymphoma kinase; Atypical; Cryptic; False negative; Non-small cell lung cancer; Rearrangement

Mesh:

Substances:

Year:  2020        PMID: 32128622     DOI: 10.1007/s00432-020-03166-1

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  38 in total

1.  Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing.

Authors:  Christina Selinger; Wendy Cooper; Trina Lum; Catriona McNeil; Adrienne Morey; Paul Waring; Benhur Amanuel; Michael Millward; Joanne Peverall; Chris Van Vliet; Michael Christie; Yen Tran; Connie Diakos; Nick Pavlakis; Anthony J Gill; Sandra O'Toole
Journal:  Histopathology       Date:  2015-05-24       Impact factor: 5.087

2.  [Guidenline for diagnosis and treatment of Alk and Ros1 positive non-small cell lung cancer in China].

Authors:  X C Zhang; S Lu; L Zhang; M L Liao; C L Wang; Y Cheng; G D Li; S J Mok; C Huang; X Q Liu; J Wang; M Z Wang; Y P Zhang; J Y Zhou; X J Zhou; X Y Zhou; D M Lin; J J Yang; Y Song; C P Hu; K Wang; Y He; H Li; W Z Zhong; Y L Wu
Journal:  Zhonghua Bing Li Xue Za Zhi       Date:  2018-04-08

Review 3.  Treatment of ALK-positive nonsmall cell lung cancer: recent advances.

Authors:  Alesha A Thai; Benjamin J Solomon
Journal:  Curr Opin Oncol       Date:  2018-03       Impact factor: 3.645

4.  Detection of Rare Mutations in CtDNA Using Next Generation Sequencing.

Authors:  Xiaoxing Lv; Meiru Zhao; Yuting Yi; Lucheng Zhang; Yanfang Guan; Tao Liu; Ling Yang; Rongrong Chen; Jianhui Ma; Xin Yi
Journal:  J Vis Exp       Date:  2017-08-24       Impact factor: 1.355

5.  Evaluating the effectiveness of RNA in-situ hybridization for detecting lung adenocarcinoma with anaplastic lymphoma kinase rearrangement.

Authors:  Naoki Nakajima; Akihiko Yoshizawa; Kyoko Kondo; Mariyo Rokutan-Kurata; Masahiro Hirata; Ayako Furuhata; Shinji Sumiyoshi; Makoto Sonobe; Toshi Menju; Masanobu Momose; Masakazu Fujimoto; Hiroshi Date; Hironori Haga
Journal:  Histopathology       Date:  2017-04-19       Impact factor: 5.087

6.  ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH.

Authors:  Eugen C Minca; Bryce P Portier; Zhen Wang; Christopher Lanigan; Carol F Farver; Yan Feng; Patrick C Ma; Valeria A Arrossi; Nathan A Pennell; Raymond R Tubbs
Journal:  J Mol Diagn       Date:  2013-03-13       Impact factor: 5.568

7.  ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.

Authors:  Weijie Zhao; Yoon-La Choi; Ji-Young Song; Yazhen Zhu; Qing Xu; Feng Zhang; Lili Jiang; Ju Cheng; Guangjuan Zheng; Mao Mao
Journal:  Lung Cancer       Date:  2016-01-21       Impact factor: 5.705

8.  Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer.

Authors:  Shengxiang Ren; Fred R Hirsch; Marileila Varella-Garcia; Dara L Aisner; Theresa Boyle; Caicun Zhou; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2014-03       Impact factor: 15.609

Review 9.  A new look at the ALK gene in cancer: copy number gain and amplification.

Authors:  Federica Zito Marino; Gaetano Rocco; Alessandro Morabito; Chiara Mignogna; Martina Intartaglia; Giuseppina Liguori; Gerardo Botti; Renato Franco
Journal:  Expert Rev Anticancer Ther       Date:  2016-04-06       Impact factor: 4.512

10.  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Authors:  Manabu Soda; Young Lim Choi; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Shunpei Ishikawa; Shin-ichiro Fujiwara; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Masashi Bando; Shoji Ohno; Yuichi Ishikawa; Hiroyuki Aburatani; Toshiro Niki; Yasunori Sohara; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Nature       Date:  2007-07-11       Impact factor: 49.962

View more
  3 in total

1.  Evaluating Solid Lung Adenocarcinoma Anaplastic Lymphoma Kinase Gene Rearrangement Using Noninvasive Radiomics Biomarkers.

Authors:  De-Ning Ma; Xin-Yi Gao; Yi-Bo Dan; An-Ni Zhang; Wei-Jun Wang; Guang Yang; Hong-Zhou Zhu
Journal:  Onco Targets Ther       Date:  2020-07-16       Impact factor: 4.147

2.  A novel fusion between CDC42BPB and ALK in a patient with quadruple wild-type gastrointestinal stromal tumor.

Authors:  Wen Huang; Wei Yuan; Lei Ren; Chen Xu; Rongkui Luo; Yuhong Zhou; Weiqi Lu; Qing Hao; Mian Xu; Yingyong Hou
Journal:  Mol Genet Genomic Med       Date:  2022-03-23       Impact factor: 2.473

3.  Clinical evaluation of the effectiveness of fusion-induced asymmetric transcription assay-based reverse transcription droplet digital PCR for ALK detection in formalin-fixed paraffin-embedded samples from lung cancer.

Authors:  Yuanyuan Liu; Shafei Wu; Xiaohua Shi; Linping Lu; Lingxiang Zhu; Yong Guo; Li Zhang; Xuan Zeng
Journal:  Thorac Cancer       Date:  2020-06-16       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.